FDA approves abuse-deterrant formulation MorphaBond (morphine sulfate extended-release) for pain management- Inspirion Delivery Technologies

The FDA has approved MorphaBond (morphine sulfate extended-release) tablets, for oral use, from Inspirion Delivery Technologies. MorphaBond is an abuse-deterrent formulation of ER-morphine using physical and chemical barriers, without the use of aversive agents or opioid antagonists.

MorphaBond is formulated with inactive ingredients that make the tablet more difficult to adulterate for misuse and abuse while maintaining extended-release characteristics even if the tablet is subjected to physical manipulation, and/or chemical extraction. MorphaBond has been tested in vitro using methods of manipulation that drug abusers commonly use for preparation of extended-release opioids for administration by various routes, including oral consumption, intranasal insufflation, injection and smoking.